SAN DIEGO, May 3, 2017 /PRNewswire/ -- Viking Therapeutics,
Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical
company focused on the development of novel therapies for metabolic
and endocrine disorders, announced today that the company will
release financial results for the first quarter of 2017, after the
market close on Wednesday, May 10,
2017.
Brian Lian, Ph.D., Viking's
president and chief executive officer, and Michael Morneau, Viking's chief financial
officer, will host a conference call to discuss financial results
and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, May 10, 2017.
To participate on the conference call, please dial (844)
850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In
addition, following the completion of the call, a telephone replay
will be accessible until May 17, 2017
by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from
outside the U.S. and entering conference ID # 10106263. Those
interested in listening to the conference call live via the
internet may do so by visiting the Investor Relations section of
Viking's website at www.vikingtherapeutics.com. An archive of the
webcast will be available for 30 days on the company's website at
www.vikingtherapeutics.com.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development of novel, first-in-class or
best-in-class therapies for metabolic and endocrine
disorders. The company's research and development activities
leverage its expertise in metabolism to develop innovative
therapeutics designed to improve patients' lives. Viking has
exclusive worldwide rights to a portfolio of five therapeutic
programs in clinical trials or preclinical studies, which are based
on small molecules licensed from Ligand Pharmaceuticals
Incorporated. The company's clinical programs include VK5211,
an orally available, non-steroidal selective androgen receptor
modulator, or SARM, in Phase 2 development for the treatment and
prevention of lean body mass loss in patients who have undergone
hip fracture surgery, VK2809, a small molecule thyroid beta agonist
in Phase 2 development for hypercholesterolemia and fatty liver
disease, and VK0612, a first-in-class, orally available drug
candidate in Phase 2 development for type 2 diabetes. Viking
also plans to initiate a proof-of-concept study of VK2809 in
patients with glycogen storage disease type Ia. The company
is also developing novel and selective agonists of the thyroid beta
receptor for adrenoleukodystrophy, as well as two earlier-stage
programs targeting metabolic diseases and anemia.
Follow Viking on Twitter @Viking_VKTX.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-first-quarter-2017-after-market-close-on-may-10-2017-300450099.html
SOURCE Viking Therapeutics, Inc.